• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Comera Life Sciences Holdings Inc.

    8/24/23 8:20:06 AM ET
    $CMRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $CMRA alert in real time by email
    SC 13G 1 ea183895-sc13gnich_comera.htm SCHEDULE 13G

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934
    (Amendment No. )*

     

    Comera Life Sciences Holdings, Inc.

    (Name of Issuer)

     

    Common Stock, par value $0.0001

     

    (Title of Class of Securities)

     

    20037C108

     

    (CUSIP Number)

     

    May 19, 2022

     

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ☐Rule 13d-1(b)

     

    ☒Rule 13d-1(c)

     

    ☐Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No. 20037C108
    1. Names of Reporting Persons
    Purchase Capital LLC
    2. Check the Appropriate Box if a Member of a Group (See Instructions)
      (a) ☐
      (b) ☐
    3. SEC Use Only
    4. Citizenship or Place of Organization
    State of Delaware
    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    5. Sole Voting Power
    -0-
    6. Shared Voting Power
    1,445,448 (1)
    7. Sole Dispositive Power
     -0-
    8. Shared Dispositive Power
    1,445,448 (1)
    9. Aggregate Amount Beneficially Owned by Each Reporting Person
    1,445,448 (1)
    10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ☐
    11. Percent of Class Represented by Amount in Row (9)
    5.17% (1)
    12. Type of Reporting Person (See Instructions)
    OO

     

    (1)All of the securities of Comera Life Sciences Holdings, Inc. (the “Issuer”) beneficially owned by Purchase Capital LLC (“Purchase Capital”) may be deemed to be beneficially owned by Nicholas J. Singer as the Managing Partner of Purchase Capital. In connection with the consummation of OTR Acquisition Corp.’s (“OTR”) business combination with the Issuer, on May 19, 2022, Purchase Capital’s ownership interests in OTR were exchanged for 421,759 shares of the Issuer’s common stock (“Shares”) and warrants to purchase 762,634 Shares (“Warrants”), representing 5.97% of the total number of Shares outstanding as of such date. On August 11, 2023, OTR Acquisition Sponsor LLC made a pro rata distribution of Shares to its members, including a distribution of 261,055 Shares to PC SPAC Holdings LLC, of which Purchase Capital is the Sole Member and may be deemed to beneficially own the Shares held by PC SPAC Holdings LLC. As of the date of this Schedule 13G, 1,445,448 Shares (including 762,634 Shares issuable upon exercise of Warrants) are beneficially owned by Purchase Capital, representing 5.17% of the total number of Shares outstanding as reported in the Issuer’s Quarterly Report on Form 10-Q filed on August 10, 2023.

     

    1

     

     

    CUSIP No. 20037C108
    1. Names of Reporting Persons
    Nicholas J. Singer
    2. Check the Appropriate Box if a Member of a Group (See Instructions)
      (a) ☐
      (b) ☐
    3. SEC Use Only
    4. Citizenship or Place of Organization
    United States
    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    5. Sole Voting Power
    1,445,448 (1)
    6. Shared Voting Power
    -0-
    7. Sole Dispositive Power
    1,445,448 (1)
    8. Shared Dispositive Power
    -0-
    9. Aggregate Amount Beneficially Owned by Each Reporting Person
    1,445,448 (1)
    10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ☐
    11. Percent of Class Represented by Amount in Row (9)
    5.17% (1)
    12. Type of Reporting Person (See Instructions)
    IN

     

    (1)As the Managing Partner of Purchase Capital, Nicholas J. Singer has sole voting power and sole dispositive power over all of the Shares held by Purchase Capital and may be deemed to be the beneficial owner of all of the Shares beneficially owned by Purchase Capital. As of May 19, 2022, Nicholas J. Singer may be deemed to beneficially own 1,184,393 Shares (including 762,634 Shares issuable upon exercise of Warrants), representing 5.97% of the total number of Shares outstanding as of such date. As of the date of this Schedule 13G, Nicholas J. Singer may be deemed to beneficially own 1,445,448 Shares (including 762,634 Shares issuable upon exercise of Warrants), representing 5.17% of the total number of Shares outstanding as reported in the Issuer’s Quarterly Report on Form 10-Q filed on August 10, 2023.

     

    2

     

     

    Item 1.
     
      (a)

    Name of Issuer

     
    Comera Life Sciences Holdings, Inc.

         
      (b)

    Address of Issuer’s Principal Executive Offices

     

    12 Gill Street, Suite 4650

    Woburn, Massachusetts 01801

     
    Item 2.
     
      (a)

    Name of Person Filing

     

    Nicholas J. Singer, Purchase Capital LLC (together, “Reporting Persons”) (1)

         
      (b)

    Address of Principal Business Office or, if none, Residence:

     

    Reporting Persons – 1395 Brickell Avenue, Suite 800, Miami, FL 33131

         
      (c)

    Citizenship

     

    Nicholas J. Singer is a United States citizen

    Purchase Capital LLC is organized under the laws of the State of Delaware

         
      (d)

    Title of Class of Securities

     

    Common Stock, par value $0.0001

         
      (e)

    CUSIP Number

     

    20037C108

       
    Item 3. If this statement is filed pursuant to Rules 13d-1(b) or 13d-2(b) or (c), check whether the person filing is a:
       
     

    Not Applicable.

     

     

    (1)Neither the present filing nor anything contained herein shall be construed as an admission that the Reporting Persons constitute a “group” for any purpose and each expressly disclaims membership in a group.

     

    3

     

     

    Item 4. Ownership
       
    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.
     
      (a)

    Amount beneficially owned:

     

    See the responses to Item 9 on the attached cover page.

         
      (b)

    Percent of class:

     

    See the responses to Item 11 on the attached cover page.

         
      (c)

    Number of shares as to which the person has:

     

         
        (i)

    Sole power to vote or to direct the vote

     

    See the responses to Item 5 on the attached cover page.

           
        (ii)

    Shared power to vote or to direct the vote

     

    See the responses to Item 6 on the attached cover page.

           
        (iii)

    Sole power to dispose or to direct the disposition of

     

    See the responses to Item 7 on the attached cover page.

           
        (iv)

    Shared power to dispose or to direct the disposition of

     

    See the responses to Item 8 on the attached cover page.

     

    Item 5. Ownership of 5 Percent or Less of a Class
       
      If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☐.
     
    Item 6. Ownership of More than 5 Percent on Behalf of Another Person
       
      Not Applicable.
     
    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person
       
      Not Applicable.
     
    Item 8. Identification and Classification of Members of the Group
       
      Not Applicable.
     
    Item 9. Notice of Dissolution of Group
       
      Not Applicable.

     

    Item 10. Certification
       
      By signing below, I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

    [Signature page to follow]

     

    4

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Date: August 24, 2023

     

      PURCHASE CAPITAL LLC
       
      By: /s/ Nicholas J. Singer
        Nicholas J. Singer
        Managing Partner
         
        NICHOLAS J. SINGER
       
        /s/ Nicholas J. Singer

     

    5

     

    Get the next $CMRA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CMRA

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $CMRA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D filed by Comera Life Sciences Holdings Inc.

      SC 13D - Comera Life Sciences Holdings, Inc. (0001907685) (Subject)

      1/5/24 7:16:15 PM ET
      $CMRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13D/A filed by Comera Life Sciences Holdings Inc. (Amendment)

      SC 13D/A - Comera Life Sciences Holdings, Inc. (0001907685) (Subject)

      9/7/23 8:05:22 PM ET
      $CMRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Comera Life Sciences Holdings Inc. (Amendment)

      SC 13G/A - Comera Life Sciences Holdings, Inc. (0001907685) (Subject)

      9/6/23 4:24:17 PM ET
      $CMRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CMRA
    Leadership Updates

    Live Leadership Updates

    See more
    • Comera Life Sciences Appoints Dorothy Clarke to Board of Directors

      WOBURN, Mass., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. (NASDAQ:CMRA), a life sciences company developing a new generation of biologic medicines to improve patient access, safety, and convenience, today announced it appointed Dorothy Clarke to its board of directors. "Dorothy's extensive experience will help Comera continue to deliver on its mission of delivering transformative solutions that have the potential to revolutionize the way we administer essential medicines," said Jeffrey Hackman, Chairman and Chief Executive Officer of Comera. Ms. Clarke previously held leadership roles at Johnson & Johnson for over 20 years, including in law, regulatory, compl

      11/13/23 8:00:19 AM ET
      $CMRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • HDAX THERAPEUTICS ANNOUNCES APPOINTMENT OF DRS. ROMAN FLECK AND NEAL I. MUNI TO BOARD OF DIRECTORS

      Appointment of veteran industry executives adds broad experience to HDAX team. MISSISSAUGA, ON, April 11, 2023 /PRNewswire/ -- HDAX Therapeutics, Inc., ("HDAX"), a privately-held pharmaceutical company developing therapeutics for neurological and cardiac diseases stemming from microtubule dysfunction, today announced the appointment of Roman Fleck, Ph.D. as Executive Chairman of the Board and Neal I. Muni, M.D., MSPH, as an independent Board member. "HDAX's platform technology has great potential to deliver breakthrough treatments where there is high unmet need.""We are please

      4/11/23 9:04:00 AM ET
      $CMRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Comera Life Sciences Appoints Janice Marie McCourt as Chief Business Officer

      WOBURN, Mass., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. (NASDAQ:CMRA), a life sciences company developing a new generation of bio-innovative biologic medicines to improve patient delivery, access, safety and convenience, today announced the appointment of Janice Marie McCourt as Chief Business Officer. In her role at Comera, Ms. McCourt will be responsible for business development, including evaluation and execution of out-licensing, in-licensing and strategic transaction opportunities, and driving the execution of the Company's commercial strategy. Ms. McCourt will report to Jeffrey Hackman, Chairman and CEO, and serve on the Company's executive leadership te

      11/9/22 8:00:00 AM ET
      $CMRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CMRA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Campbell Michael Gerard bought $708 worth of shares (10,000 units at $0.07), increasing direct ownership by 40% to 35,000 units (SEC Form 4)

      4 - Comera Life Sciences Holdings, Inc. (0001907685) (Issuer)

      11/28/23 4:25:36 PM ET
      $CMRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CMRA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $CMRA
    Financials

    Live finance-specific insights

    See more

    $CMRA
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $CMRA
    SEC Filings

    See more
    • SEC Form 4 filed by Konar Shameek

      4 - Comera Life Sciences Holdings, Inc. (0001907685) (Issuer)

      2/2/24 7:48:13 PM ET
      $CMRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • New insider Konar Shameek claimed ownership of 1,001,064 shares (SEC Form 3)

      3 - Comera Life Sciences Holdings, Inc. (0001907685) (Issuer)

      2/2/24 7:47:03 PM ET
      $CMRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Denny George P Iii

      4 - Comera Life Sciences Holdings, Inc. (0001907685) (Issuer)

      1/11/24 7:14:17 PM ET
      $CMRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Comera Life Sciences Reports Financial Results for Third Quarter 2023 and Recent Business Highlights

      – Final stage of technical evaluation near completion in Comera's research collaboration with Regeneron, a leading U.S. biotechnology company – – Expanded and strengthened Comera's global patent portfolio, broadening both geographic coverage and claims for core SQore excipient technology – –   Completed previously announced $4.1 million private placement of shares of Comera's common stock, and accompanying warrants to purchase shares of its common stock, to existing stockholders – WOBURN, Mass., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. (NASDAQ:CMRA), a life sciences company developing a new generation of biologic medicines to improve patient access, safety,

      11/9/23 8:00:00 AM ET
      $CMRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Comera Life Sciences Reports Financial Results for Second Quarter 2023 and Recent Business Highlights

      – Advanced to final stage of technical evaluation in Comera's research collaboration with Regeneron, a leading U.S. biotechnology company – – Received notice that Nasdaq granted Comera's request for the continued listing of its common stock, subject to Comera's satisfaction of certain conditions – – Strengthened cash position with execution of a definitive agreement in July to complete a $4.1 million private placement of shares of its common stock, and accompanying warrants to purchase shares of its common stock, to existing stockholders – – Significantly expanded intellectual property portfolio, broadening both geographic coverage and claims for core SQore™ excipient technology – WOBURN

      8/10/23 8:00:00 AM ET
      $CMRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Comera Life Sciences Reports Financial Results for First Quarter 2023 and Recent Business Highlights

      – Significant progress in Comera's ongoing research collaboration with Regeneron, a leading U.S. biotechnology company – – Further development of Comera's pipeline candidate CLS-001 (SQ vedolizumab), highlighted by identification of a lead formulation – – Expanded Comera's patent portfolio, broadening geographic coverage as well as scope of claims for core SQore™ excipient technology – WOBURN, Mass., May 11, 2023 (GLOBE NEWSWIRE) --  Comera Life Sciences Holdings, Inc. (NASDAQ:CMRA), a life sciences company developing a new generation of bio-innovative biologic medicines to improve patient access, safety, and convenience, today reported financial results for the first quarter ende

      5/11/23 8:30:00 AM ET
      $CMRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Comera Life Sciences Announces Bridge Financing and Exercise of Take Private Option

      WOBURN, Mass., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. (OTCQB:CMRA) ("Comera" or the "Company"), a life sciences company developing a proprietary drug-delivery technology to improve patient access, safety, and convenience, today announced the closing of a bridge financing with a syndicate of investors. Following the closing, the investors exercised a purchase option to acquire all of the outstanding common stock of the Company not already held by the investors to take the Company private. The financing and option exercise follows a robust effort by the Company, led by a Special Committee of the Company's Board of Directors, to explore strategic alternatives to

      1/4/24 8:30:00 AM ET
      $CMRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Comera Life Sciences Announces Process Exploring Strategic Alternatives

      WOBURN, Mass., Dec. 06, 2023 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. (OTCQB:CMRA) ("Comera" or the "Company"), a life sciences company developing a new generation of biologic medicines to improve patient access, safety, and convenience, today announced that it has initiated a process to explore strategic alternatives to maximize shareholder value. As part of its process, Comera is exploring the potential for an acquisition, company sale, merger, divestiture of assets, licensing, or other strategic transactions and/or seeking additional financing. There is no set timetable for this process and there can be no assurance that this process will result in the Company pursuing a

      12/6/23 8:30:00 AM ET
      $CMRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Comera Life Sciences Appoints Dorothy Clarke to Board of Directors

      WOBURN, Mass., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. (NASDAQ:CMRA), a life sciences company developing a new generation of biologic medicines to improve patient access, safety, and convenience, today announced it appointed Dorothy Clarke to its board of directors. "Dorothy's extensive experience will help Comera continue to deliver on its mission of delivering transformative solutions that have the potential to revolutionize the way we administer essential medicines," said Jeffrey Hackman, Chairman and Chief Executive Officer of Comera. Ms. Clarke previously held leadership roles at Johnson & Johnson for over 20 years, including in law, regulatory, compl

      11/13/23 8:00:19 AM ET
      $CMRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form EFFECT filed by Comera Life Sciences Holdings Inc.

      EFFECT - Comera Life Sciences Holdings, Inc. (0001907685) (Filer)

      2/28/24 12:15:18 AM ET
      $CMRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form EFFECT filed by Comera Life Sciences Holdings Inc.

      EFFECT - Comera Life Sciences Holdings, Inc. (0001907685) (Filer)

      2/28/24 12:15:27 AM ET
      $CMRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form EFFECT filed by Comera Life Sciences Holdings Inc.

      EFFECT - Comera Life Sciences Holdings, Inc. (0001907685) (Filer)

      2/28/24 12:15:16 AM ET
      $CMRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care